for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IVERIC bio Inc

ISEE.O

Latest Trade

6.88USD

Change

0.37(+5.61%)

Volume

1,048,779

Today's Range

6.50

 - 

6.92

52 Week Range

3.56

 - 

7.98

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.51
Open
6.56
Volume
1,048,779
3M AVG Volume
11.85
Today's High
6.92
Today's Low
6.50
52 Week High
7.98
52 Week Low
3.56
Shares Out (MIL)
90.26
Market Cap (MIL)
620.50
Forward P/E
-7.10
Dividend (Yield %)
--

Next Event

Iveric Bio Inc Annual Shareholders Meeting

Latest Developments

More

Iveric Bio Reports Q1 Loss Per Share $0.29

Iveric Bio Files For Mixed Shelf Of Upto $300 Mln

Iveric Bio Reports Q4 Loss Per Share $0.27

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IVERIC bio Inc

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company’s therapeutics portfolio consists of its clinical stage product candidate Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, its preclinical product candidate from its High temperature requirement A serine peptidase one protein (HtrA1), inhibitors program. Its lead gene therapy products also includes IC-100 and IC-200.

Industry

Biotechnology & Drugs

Contact Info

5 Penn Plaza, Suite 2372

NEW YORK, NY

10001

United States

+1.212.8458200

https://ivericbio.com/

Executive Leadership

David R. Guyer

Executive Chairman of the Board

Pravin U. Dugel

President

Glenn P. Sblendorio

Chief Executive Officer, Director

David Francis Carroll

Chief Financial Officer, Senior Vice President, Treasurer

Keith Westby

Chief Operating Officer, Senior Vice President

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-1.670

2019

-1.390

2020

-1.140

2021(E)

-0.917
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-70.79
Return on Equity (TTM)
-63.52

Latest News

Latest News

BRIEF-Iveric Bio Reports First Patient Dosed In Second Zimura Phase 3 Trial

* IVERIC BIO ANNOUNCES FIRST PATIENT DOSED IN SECOND ZIMURA® PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION Source text for Eikon: Further company coverage:

BRIEF-Iveric Bio Inc Announces Pricing Of Upsized Public Offering Of Common Stock at $4.100 Per Share

* ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BRIEF-Iveric Bio Announces Proposed Offering Of Common Stock And Pre-Funded Warrants And Concurrent Private Placement

* IVERIC BIO, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS AND CONCURRENT PRIVATE PLACEMENT

BRIEF-Iveric Bio Posts Q1 Loss Per Share Of $0.28

* IVERIC BIO REPORTS FIRST QUARTER 2020 OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Iveric Bio Announces Fast Track Designation From U.S. FDA For Zimura®

* IVERIC BIO ANNOUNCES FAST TRACK DESIGNATION FROM U.S. FDA FOR ZIMURA® FOR THE TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION Source text for Eikon: Further company coverage:

BRIEF-Iveric Bio Appoints Pravin U. Dugel, MD, As Executive Vice President And Chief Strategy And Business Officer

* IVERIC BIO APPOINTS PRAVIN U. DUGEL, MD, AS EXECUTIVE VICE PRESIDENT AND CHIEF STRATEGY AND BUSINESS OFFICER Source text for Eikon: Further company coverage:

FDA urges virtual patient visits as coronavirus disrupts clinical trials

The U.S. Food and Drug Administration on Wednesday recommended switching to virtual patient visits instead of in-person monitoring for clinical studies, as signs emerge that the rapid spread of the coronavirus outbreak is disrupting trials.

U.S. companies begin delaying clinical trials due to coronavirus outbreak

U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as the drug developer said it would postpone recruitment for a trial of its eye disease drug.

BRIEF-Iveric Bio Reports Q4 Loss Per Share $0.39

* IVERIC BIO REPORTS FOURTH QUARTER AND YEAR END 2019 OPERATIONAL HIGHLIGHTS AND FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up